The long-term use of levodopa (L-DOPA) in Parkinson's disease (PD) results in the development of abnormal involuntary movements called L-DOPA-induced dyskinesias. Increasing evidences suggest that the endocannabinoid system may play a role in the modulation of dyskinesias. In this work, we assessed the antidyskinetic effect of the endocannabinoid analog oleoylethanolamide (OEA), an agonist of PPARα and antagonist of TRPV1 receptors. We used a hemiparkinsonian model of PD in mice with 6-OHDA striatal lesion. The chronic L-DOPA treatment developed intense axial, forelimb and orolingual dyskinetic symptoms, as well as contralateral rotations. Treatment with OEA reduced all these symptoms without reducing motor activity or the therapeutic motor effects of L-DOPA. Moreover, the OEA-induced reduction in dyskinetic behavior correlated with a reduction in molecular correlates of dyskinesia. OEA reduced FosB striatal overexpression and phosphoacetylation of histone 3, both molecular markers of L-DOPA-induced dyskinesias. We found that OEA antidyskinetic properties were mediated by TRPV1 receptor, as pretreatment with capsaicin, a TRPV1 agonist, blocked OEA antidyskinetic actions, as well as the reduction in FosB-and pAcH3-overexpression induced by L-DOPA. This study supports the hypothesis that the endocannabinoid system plays an important role in the development and expression of dyskinesias and might be an effective target for the treatment of L-DOPA-induced dyskinesias. Importantly, there was no development of tolerance to OEA in any of the parameters we examined, which has important implications for the therapeutic potential of drugs targeting the endocannabinoid system.
Introduction
Parkinson's disease (PD) is a progressive, chronic and age-associated neurodegenerative disorder characterized by a dramatic depletion of dopamine (DA) in the striatum due to loss of dopaminergic neurons of the substantia nigra pars compacta (SNpc). Levodopa (L-DOPA) is the most commonly used treatment for PD. Initially, it improves all PD symptoms, but its therapeutic efficacy wanes with time and side effects appear in chronically treated patients, including motor fluctuations, "on-off" periods, and abnormal involuntary movements (AIMs) known as L-DOPA-induced dyskinesias (Jenner, 2004; Marsden, 1994) . The development of dyskinesias is attributed to a sequence of striatal events that occur following repeated L-DOPA administration, including pulsatile stimulation of DA receptors and the complete denervation of areas within the striatum. These result in sensitization of responses to DA, and shortand long-term maladaptative synaptic plasticity (Cenci and Lundblad, 2006; Pavón et al., 2006) . Several studies have associated dyskinesias with increased expression of diverse molecular markers, including overexpression of FosB and dynorphin, phosphorylation of ERK1/2 and phospho-acetylation of histone 3 (Pavón et al., 2006; Santini et al., 2007) . Interestingly, only the D1 dopamine receptor, not D2, seems to be critical in these underlying molecular changes (Darmopil et al., 2009; Murer and Moratalla, 2011; Santini et al., 2009) .
Increasing evidence suggests that non-dopaminergic mechanisms also contribute to dyskinesias (Brotchie, 2005) , including several lines of evidence indicating a role for the endocannabinoid system. The endocannabinoid system is particularly abundant in the basal ganglia circuit (Bisogno et al., 1999; Devane et al., 1992; Egertova et al., 2003; Mailleux and Vanderhaeghen, 1992; Martín et al., 2008; Suárez et al., 2011) , and cannabinoid modulation of GABA and glutamate synaptic transmission has important influences on all dopamine-mediated motor mechanisms (Di Marzo et al., 1998; Julian et al., 2003; Martín et al., 2008) . The receptors primarily involved in cannabinoid-mediated effects are CB1 and CB2, but the endocannabinoid system also includes nuclear peroxisome proliferator-activated receptor α (PPARα) and transient receptor potential vanilloid subtype 1 (TRPV1) (Devane et al., 1988; Munro et al., 1993; Smart et al., 2000; Sun and Bennett, 2007) .
Based on well documented changes in CB1 expression and endocannabinoid levels in response to L-DOPA administration (Ferrer et al., 2003; Zeng et al., 1999) , cannabinoids have been investigated in many Neurobiology of Disease 62 (2014) [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] 
